InsidersTradesSigma
Follow the Median Technologies share price and the full directors' dealings record of the company, a listed equity based in France. Shares trade on the FR market, under the oversight of AMF. Operating in the Healthcare & Pharma sector, Median Technologies has published 60 insider filings. Market capitalisation: €214.7m. The latest transaction was disclosed on 2 July 2026 (Exercice). Among the most active insiders: Nicolas Dano. Every trade is free.
60
Insider Decl.
n/a
Thresholds
€475,658
15 ops.
Buy Volume
€3m
18 ops.
Sell Volume
43Σ signal
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 2 July 2026
Declarations60 total
50,000 shares@ €1.500.032% mcap100.0% of flowOption d'achatEuronext Growth ParisISIN FR00110498242026DD1124436
84,516 shares@ €1.500.057% mcap4.2% of flowOption d'achatEuronext Growth ParisISIN FR00110498242026DD1123798
12,773 shares@ €1.500.0097% mcap8.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242026DD1122041
15,000 shares@ €3.20100.0% of flowActionEuronext Growth ParisISIN FR00110498242025DD1068467
7,500 shares@ €3.2012.0% of flowActionEuronext Growth ParisISIN FR00110498242025DD1065529
Canonical exit: 19 Jan 2026 (T+90)
2,000 shares@ €3.193.2% of flowActionEuronext Growth ParisISIN FR00110498242025DD1059415
60,241 shares@ €1.6631.7% of flowActionEuronext Growth ParisISIN FR00110498242025DD1058078
Canonical exit: 3 Nov 2025 (T+90)
4,000 shares@ €2.8455.7% of flowActionEuronext Growth ParisISIN FR00110498242025DD1057596
2,000 shares@ €2.692.7% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053940
2,000 shares@ €2.322.3% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053604
60,242 shares@ €1.6649.9% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053614
Canonical exit: 3 Nov 2025 (T+90)
2,000 shares@ €1.9942.0% of flowActionEuronext Growth ParisISIN FR00110498242025DD1053615
60,241 shares@ €1.663.4% of flowActionEuronext Growth ParisISIN FR00110498242025DD1052971
Canonical exit: 3 Nov 2025 (T+90)
1,000 shares@ €5.87512.9% of flowActionEuronext Growth ParisISIN FR00110498242024DD994378
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994379
1,000 shares@ €5.35752.7% of flowActionEuronext Growth ParisISIN FR00110498242024DD994380
1,000 shares@ €4.96442.5% of flowActionEuronext Growth ParisISIN FR00110498242024DD994372
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994373
1,000 shares@ €6.70723.3% of flowActionEuronext Growth ParisISIN FR00110498242024DD994374
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994375
1,000 shares@ €5.33642.7% of flowActionEuronext Growth ParisISIN FR00110498242024DD994376
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994377
1,000 shares@ €1.500.7% of flowOption d'achatEuronext Growth ParisISIN FR00110498242024DD994369
15,000 shares@ €4.45100.0% of flowActionEuronext ParisISIN FR00110498242023DD942067
Canonical exit: 19 Jan 2024 (T+90)
28,000 shares0ACTIONS GRATUITES AGAEuronext Growth ParisISIN FR00110498242023DD939339
Canonical exit: 22 Jan 2024 (T+90)
25 of 60 declarations
关于 Median Technologies
Median Technologies 是一家法国医疗科技公司，在巴黎泛欧交易所增长板上市，股票代码为 ALMDT，ISIN FR0011049824。该公司由 Fredrik Brag 于 2002 年创立，其核心业务围绕医学影像、人工智能和肿瘤学图像分析方面的先进专业知识。其市场定位是专注于高价值软件和服务的医疗科技/健康科技专家，旨在帮助改善早期癌症诊断并加速新疗法的开发。在其最近的沟通中，Median 将自己描述为一家开发用于早期癌症检测的人工智能医疗软件公司，以及一家为肿瘤药物开发商提供全球领先的中央影像服务和图像分析供应商。该公司还符合法国的 PEA-PME 计划，这突显了其中型市值和增长导向的定位。 Median Technologies 的业务围绕两大支柱展开。第一个是 iCRO，一项针对肿瘤学临床试验的影像服务活动。通过该部门，公司支持生物制药合作伙伴进行临床研究的设计、监测和分析，提供中央图像判读、数据管理和高级影像分析。第二个支柱是 eyonis™，这是一套由人工智能驱动的医疗器械软件 (SaMD)，专为早期癌症检测而设计，特别侧重于肺癌筛查。这种双重模式为 Median 带来了经常性服务收入和长期的软件增长潜力，随着 SaaS/SaMD 平台的规模化，利润率有望提高。 该公司在医学影像、人工智能和肿瘤学的交叉领域占据战略利基市场。它通过提供能够提高诊断准确性并缩短肿瘤药物开发时间表的工具，来解决尚未满足的重大医疗需求。其客户群包括参与癌症临床试验的大型国际制药公司。Median 拥有国际业务，其商业和运营活动服务于欧洲、北美和其他主要临床研究市场，并由一个为多国项目设计的组织提供支持。该公司的显著特点包括其在计算机视觉、信号处理和应用于医学影像的人工智能方面的专有能力，以及围绕 eyonis™ 持续进行的临床和监管进展。
